Small-cell lung cancer (SCLC) remains the deadliest of all the lung cancer types. Its high
mortality is largely attributed to the invariable development of resistance to standard …

Background Small cell lung cancer (SCLC) is a deadly, high grade neuroendocrine (NE)
tumor without recognized morphologic heterogeneity. However, over 30 years ago we …

Precision medicine requires an understanding of cancer genes and mutational processes,
as well as an appreciation of the extent to which these are found heterogeneously in cancer …

Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic
interventions palliative rather than curative. Here we discuss the implications of how …

Recent genomic analyses have revealed substantial tumor heterogeneity across various
cancers. However, it remains unclear whether and how genomic heterogeneity is …

Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1,
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …

Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung
adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung …

Trans-differentiation from an adenocarcinoma to a small cell neuroendocrine state is
associated with therapy resistance in multiple cancer types. To gain insight into the …

Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are two main histological
subtypes of solid cancer; however, SCCs are derived from different organs with similar …

Simple Summary The cancer cells in solid tumors are embedded in a complex connective
tissue matrix composed of various other cell types, ie, mesenchymal stroma/stem-like cells …